Cargando…

P634: EARLY-STAGE MEASURABLE RESIDUAL DISEASE DYNAMICS AND IGHV REPERTOIRE RECONSTITUTION DURING VENETOCLAX AND OBINUTUZUMAB TREATMENT IN CHRONIC LYMPHOCYTIC LEUKEMIA

Detalles Bibliográficos
Autores principales:	Hengeveld, Paul, Schilperoord-Vermeulen, Joyce, van der Klift, Michèle, Dubois, Julie, Martijn Kolijn, Pieter, Kavelaars, François, Rijken, Melissa, Dobber, Johan, Nasserinejad, Kazem, Kersting, Sabina, Westerweel, Peter, Kater, Arnon, Langerak, Anton, Levin, Mark-David
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Lippincott Williams & Wilkins 2023
Materias:	Posters
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10429050/ http://dx.doi.org/10.1097/01.HS9.0000969440.63949.3f

Ejemplares similares

Early-stage measurable residual disease dynamics and IGHV repertoire reconstitution during venetoclax and obinutuzumab treatment in chronic lymphocytic leukemia
por: Hengeveld, P. J., et al.
Publicado: (2023)

Protocol description of the HOVON 141/VISION trial: a prospective, multicentre, randomised phase II trial of ibrutinib plus venetoclax in patients with creatinine clearance ≥30 mL/min who have relapsed or refractory chronic lymphocytic leukaemia (RR-CLL) with or without TP53 aberrations
por: Levin, Mark-David, et al.
Publicado: (2020)

S148: TIME-LIMITED VENETOCLAX AND IBRUTINIB FOR PATIENTS WITH RELAPSED/REFRACTORY CLL WHO HAVE UNDETECTABLE MRD – 4-YEAR FOLLOW UP FROM THE RANDOMIZED PHASE II VISION/HO141 TRIAL
por: Kater, Arnon, et al.
Publicado: (2023)

Impact of Minimal Residual Disease on Progression-Free Survival Outcomes After Fixed-Duration Ibrutinib-Venetoclax Versus Chlorambucil-Obinutuzumab in the GLOW Study
por: Munir, Talha, et al.
Publicado: (2023)

Evaluation and associated risk factors for neutropenia with venetoclax and obinutuzumab in the treatment of chronic lymphocytic leukemia
por: Samuels, Courtney, et al.
Publicado: (2021)

Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

High-throughput Proteomics Identifies THEMIS2 as Independent Biomarker of Treatment-free Survival in Untreated CLL
por: Hengeveld, Paul J., et al.
Publicado: (2023)

IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

Treatment Approaches to Chronic Lymphocytic Leukemia With High-Risk Molecular Features
por: van der Straten, Lina, et al.
Publicado: (2021)

Combined Patterns of IGHV Repertoire and Cytogenetic/Molecular Alterations in Monoclonal B Lymphocytosis versus Chronic Lymphocytic Leukemia
por: Henriques, Ana, et al.
Publicado: (2013)

Erratum: IGHV1-69 polymorphism modulates anti-influenza antibody repertoires, correlates with IGHV utilization shifts and varies by ethnicity
por: Avnir, Yuval, et al.
Publicado: (2016)

Author Correction: Transcriptomic profiles and 5-year results from the randomized CLL14 study of venetoclax plus obinutuzumab versus chlorambucil plus obinutuzumab in chronic lymphocytic leukemia
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

P1090: LONG TERM FOLLOW-UP OF UNTREATED/RELAPSING MCL PATIENTS WITH THE IBRUTINIB, OBINUTUZUMAB, AND VENETOCLAX COMBINATION.
por: Le Gouill, Steven, et al.
Publicado: (2023)

S140: IBRUTINIB SENSITIZES CLL CELLS TO VENETOCLAX BY INTERRUPTING TLR9-INDUCED CD40 UPREGULATION AND PROTEIN TRANSLATION
por: Kielbassa, Karoline, et al.
Publicado: (2023)

Tipping the balance: toward rational combination therapies to overcome venetoclax resistance in mantle cell lymphoma
por: Thus, Yvonne J., et al.
Publicado: (2022)

P1713: VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN FIRST LINE CHRONIC LYMPHOCYTIC LEUKEMIA IN ARGENTINA: A COST-EFFECTIVENESS ANALYSIS
por: Kanevsky, D., et al.
Publicado: (2022)

SAKK 35/15: a phase 1 trial of obinutuzumab in combination with venetoclax in patients with previously untreated follicular lymphoma
por: Stathis, Anastasios, et al.
Publicado: (2022)

A Probabilistic Cost-Effectiveness Analysis of Venetoclax and Obinutuzumab as a First-Line Therapy in Chronic Lymphocytic Leukemia in Canada
por: Chatterjee, Anuja, et al.
Publicado: (2022)

S145: VENETOCLAX-OBINUTUZUMAB FOR PREVIOUSLY UNTREATED CHRONIC LYMPHOCYTIC LEUKEMIA: 6-YEAR RESULTS OF THE RANDOMIZED CLL14 STUDY
por: Al-Sawaf, Othman, et al.
Publicado: (2023)

Ibrutinib sensitizes CLL cells to venetoclax by interrupting TLR9-induced CD40 upregulation and protein translation
por: Kielbassa, Karoline, et al.
Publicado: (2023)

PB1869: IGHV REPERTOIRE FEATURES IN KAZAKHSTAN CHRONIC LYMPHOCYTIC LEUKEMIA PATIENTS
por: Klodzinskiy, A., et al.
Publicado: (2022)

COVID-19 among fit patients with CLL treated with venetoclax-based combinations
por: Fürstenau, Moritz, et al.
Publicado: (2020)

Venetoclax plus bendamustine-rituximab or bendamustine-obinutuzumab in chronic lymphocytic leukemia: final results of a phase Ib study (GO28440)
por: Stilgenbauer, Stephan, et al.
Publicado: (2020)

Complete eradication of chronic lymphocytic leukemia with unusual skin involvement of high mitotic index after time‐limited venetoclax/obinutuzumab treatment
por: Dimou, Maria, et al.
Publicado: (2021)

Next-Generation Sequencing Analysis of the Human TCRγδ+ T-Cell Repertoire Reveals Shifts in Vγ- and Vδ-Usage in Memory Populations upon Aging
por: Kallemeijn, Martine J., et al.
Publicado: (2018)

Minimal Residual Disease Dynamics after Venetoclax-Obinutuzumab Treatment: Extended Off-Treatment Follow-up From the Randomized CLL14 Study
por: Al-Sawaf, Othman, et al.
Publicado: (2021)

Pharmacokinetics and Exposure-Response Analysis of Venetoclax + Obinutuzumab in Chronic Lymphocytic Leukemia: Phase 1b Study and Phase 3 CLL14 Trial
por: Samineni, Divya, et al.
Publicado: (2022)

PB1938: REAL WORLD EFFECTIVENESS AND SAFETY OF VENETOCLAX IN COMBINATION WITH OBINUTUZUMAB IN TREATMENT NAIVE CLL PATIENTS – DATA FROM THE OBSERVATIONAL STUDY VERVE
por: Schwaner, Ingo, et al.
Publicado: (2023)

Combined ibrutinib and venetoclax treatment vs single agents in the TCL1 mouse model of chronic lymphocytic leukemia
por: Kater, Arnon P., et al.
Publicado: (2021)

Dysregulated signaling, proliferation and apoptosis impact on the pathogenesis of TCRγδ+ T cell large granular lymphocyte leukemia
por: Kallemeijn, Martine J., et al.
Publicado: (2017)

Cost-effectiveness of a 12-month fixed-duration venetoclax treatment in combination with obinutuzumab in first-line, unfit chronic lymphocytic leukemia in the United States
por: Chatterjee, Anuja, et al.
Publicado: (2021)

Depletion of CLL cells by venetoclax treatment reverses oxidative stress and impaired glycolysis in CD4 T cells
por: van Bruggen, J. A. C., et al.
Publicado: (2022)

Addressing IGHV Gene Structural Diversity Enhances Immunoglobulin Repertoire Analysis: Lessons From Rhesus Macaque
por: Kaduk, Mateusz, et al.
Publicado: (2022)

S147: EFFICACY AND SAFETY RESULTS OF MOLTO, A MULTICENTER, OPEN LABEL, PHASE II CLINICAL TRIAL EVALUATING VENETOCLAX, ATEZOLIZUMAB AND OBINUTUZUMAB COMBINATION IN RICHTER SYNDROME
por: Frustaci, Anna Maria, et al.
Publicado: (2023)

IGHV-associated methylation signatures more accurately predict clinical outcomes of chronic lymphocytic leukemia patients than IGHV mutation load
por: Hussmann, Dianna, et al.
Publicado: (2021)

SAT-634 The Effect of Continine Verified Smoking on the Development of Diabetes
por: Jung, Inha, et al.
Publicado: (2020)

Prognosis of IGLV3-21(R110) chronic lymphocytic leukemia after chemotherapy-based treatment in a real-world analysis
por: Hengeveld, Paul J., et al.
Publicado: (2023)

Celebrating 20 Years of IGHV Mutation Analysis in CLL
por: Chiorazzi, Nicholas, et al.
Publicado: (2020)

IGHV allele similarity clustering improves genotype inference from adaptive immune receptor repertoire sequencing data
por: Peres, Ayelet, et al.
Publicado: (2023)

A review of the incidence of tumor lysis syndrome in patients with chronic lymphocytic leukemia treated with venetoclax and debulking strategies
por: Sharman, Jeffrey P., et al.
Publicado: (2022)

Cannot write session to /tmp/vufind_sessions/sess_3fs5qkgv4eakn2lgi7t2kgg0lb